Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial.

What Was Tested

Researchers studied Anti-Arrhythmia Agents in this randomized controlled trial publication.

Their aim was to compare short-term mortality in patients with STEMI who received either intravenous magnesium sulphate or placebo.

Who Took Part

The study group was 6213 patients.

By PubMed's age tags, the people studied were older adults, both men and women.

At randomisation, patients were stratified by their eligibility for reperfusion therapy.

The first stratum included patients who were aged 65 years or older and eligible for reperfusion therapy, and the second stratum included patients of any age who were not eligible for reperfusion therapy.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Anti-Arrhythmia Agents study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Anti-Arrhythmia Agents, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Anti-Arrhythmia Agents group a baseline to be compared against.

Their primary endpoint was 30-day all-cause mortality.

What Was Measured

PubMed files the paper under topics including Anti-Arrhythmia Agents, Calcium Channel Blockers, Logistic Models, Magnesium Sulfate, Multivariate Analysis, Myocardial Infarction and Odds Ratio.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Anti-Arrhythmia Agents in 6213 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2002 (Lancet (London, England)), a journal based in England.

More context: all human trials.